Snapshot on the French Oncology Market                                         -Franco-British Business Exchange on oncolo...
1.         KEY MARKET FIGURES2.         RELEVANT NETWORKS & STAKEHOLDERS3.         FOCUS ON INDUSTRY PARTICIPANTS Presenta...
1.         KEY MARKET FIGURES2.         RELEVANT NETWORKS & STAKEHOLDERS3.         FOCUS ON INDUSTRY PARTICIPANTS Presenta...
In 2009, the French oncology therapeutic market represented a €3.3Bn opportunity, fuelled by a single-digit and slowing gr...
In 2009, over 50% of French oncology therapeutic market sales were     in the hands of three players (i.e. Roche, Sanofi-A...
Targeted therapies are the most dynamic drugs among the top 15 productsof the French oncology therapeutic market          ...
Market trends             Overview of the French Oncology Market  Roche will increase leadership thanks to wise lifecycle ...
1.         KEY MARKET FIGURES2.         RELEVANT NETWORKS & STAKEHOLDERS3.         FOCUS ON INDUSTRY PARTICIPANTS Presenta...
Customer analysis: a complex organization (!)                                                                       ARH   ...
France boasts an attractive environment in the organization of oncology careand R&D funding /support (1/2)STARTING POINT: ...
France boasts an attractive environment in the organization of oncology careand R&D funding / support (2/2)EXAMPLES OF NET...
1.         KEY MARKET FIGURES2.         RELEVANT NETWORKS & STAKEHOLDERS3.         FOCUS ON INDUSTRY PARTICIPANTS Presenta...
A dynamic network of biotech start-ups and SMEs both involvedin the development of diagnostics tools and advanced oncology...
19, rue du Général Foy       75008 Paris         France Tel: +33 1 58 05 14 00 Fax: +33 1 58 05 14 0914 Wall Street, 20th ...
Upcoming SlideShare
Loading in …5
×

Snapshot on the French Oncology Market March 2010

873 views
788 views

Published on

Published in: Health & Medicine, Technology
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
873
On SlideShare
0
From Embeds
0
Number of Embeds
24
Actions
Shares
0
Downloads
22
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Snapshot on the French Oncology Market March 2010

  1. 1. Snapshot on the French Oncology Market -Franco-British Business Exchange on oncology therapies Lyon, March 2nd 2010 Presentation of the French Oncology Market – Lyon - March 2010 1
  2. 2. 1. KEY MARKET FIGURES2. RELEVANT NETWORKS & STAKEHOLDERS3. FOCUS ON INDUSTRY PARTICIPANTS Presentation of the French Oncology Market – Lyon - March 2010 2
  3. 3. 1. KEY MARKET FIGURES2. RELEVANT NETWORKS & STAKEHOLDERS3. FOCUS ON INDUSTRY PARTICIPANTS Presentation of the French Oncology Market – Lyon - March 2010 3
  4. 4. In 2009, the French oncology therapeutic market represented a €3.3Bn opportunity, fuelled by a single-digit and slowing growth rate CAGR2 Growth Dynamics of The French oncology market1 2005-2009 2008-2009Sales (in €M) +6.0% Total 3 500 +13.1% +6.0% +13.8% 3,277.5 market 3,091.8 3 000 +12.6% 2,715.8 994.3 30% Retail +13.1% +4.7% +20.6% 950.0 2 500 2,412.9 875.2 2,000.2 704.8 2 000 607.8 30% 1 500 2 283.3 2 141.8 Hospital +13.2% +6.6% 1 000 1 840.7 1 708.1 1 392.4 70% 70% 500 0 2005 2006 2007 2008 2009 Source: GERS, Bionest Partners Presentation of the French Oncology Market – Lyon - March 2010 4
  5. 5. In 2009, over 50% of French oncology therapeutic market sales were in the hands of three players (i.e. Roche, Sanofi-Aventis and Novartis) Top 15 companies on the French oncology market in 2009 Market share 29.2% 11.9% 8.9% 5.8% 5.7% 5.5% 4.8% 3.2% 2.4% 2.3% 2.2% 2.1% 2.0% 1.9% 1.7% Cumulative 29.2% 41.8% 50.7% 56.5% 62.1% 67.6% 72.4% 75.6% 78.0% 80.2% 82.4% 84.5% 86.5% 88.4% 90.1% Market ShareSales evolution +10.7% -3.8% +12.3% -17.6% -15.3% +45.9% +2.7% -7.1% +4.7% +3.3% +35.8% +16.0% +10.2% +1.9% -2.5% vs. 2007 1,200 980.62009 sales in €M 1,000 800 600 389.2 400 291.0 189.3 185.1 179.9 158.0 200 103.2 79.1 73.9 72.0 67.6 67.0 62.4 54.9 0 E1 O H N E A ER G A ER VA S S AN E C TI TI SE G EC EN ED N A H AY AN IZ TE O YL IL U EN R C IP N G K LO R VA PF C O M B FR TA ZE EL SE AV R EN -P O A C Y N K G FI SS R LL C IN O ST ER N N LI ER JA A SA M H SC 1 Including Mabthera sales in Rheumatoid Arthritis (commercialized in this indication since Sept-06) Source: GERS, Bionest Partners Presentation of the French Oncology Market – Lyon - March 2010 5
  6. 6. Targeted therapies are the most dynamic drugs among the top 15 productsof the French oncology therapeutic market Overview of the French Oncology Market Drug market share in 2009 (in %) Bubble size represents 13.0% product sales in 2009 (in €M) Cytotoxics 12.0% AVASTIN Targeted therapies 374.2 €M Others 10.0% 8.0% HERCEPTIN 264.8 €M TAXOTERE MABTHERA1 220.9 €M 220.4 €M 6.0% GLIVEC ELOXATINE 168.1 €M REVLIMID 121.3 €M 131.1 €M 4.0% ARIMIDEX ALIMTA 112.2 €M TARCEVA 113.3 €M 76.7€M CAMPTO 81.2 €M ERBITUX 101.5 €M 2.0% VELCADE 65.4 €M ENANTONE SUTENT 62.4 €M 65.7 €M Drug incremental sales 08/09 (in €M) -40 -20 0 20 40 60 80 100 1 Including Mabthera sales in Rheumatoid Arthritis (commercialized in this indication since Sept-06)Source: GERS, Bionest Partners Presentation of the French Oncology Market – Lyon - March 2010 6
  7. 7. Market trends Overview of the French Oncology Market Roche will increase leadership thanks to wise lifecycle management initiatives and targeted partnerships with key stakeholders (e.g. InCA, learned societies) Genericization has already impacted lead players and will continue to do so (e.g. Sanofi / Taxotère) Biosimilars will become a threat, but only limited to supportive care treatments (EPO, GCSF); Mabs / targeted therapies will be challenged later (2014 onwards) Increasing governmental pressure on Price and Reimbursement of drugs Presentation of the French Oncology Market – Lyon - March 2010 7
  8. 8. 1. KEY MARKET FIGURES2. RELEVANT NETWORKS & STAKEHOLDERS3. FOCUS ON INDUSTRY PARTICIPANTS Presentation of the French Oncology Market – Lyon - March 2010 8
  9. 9. Customer analysis: a complex organization (!) ARH URCAM Europe Cellules de EORTC… Site de référence Site orienté Coordination en INSERM IARC Structures de Site de proximité Site relais SROS Cancérologie ARS référencement 3C Réseaux de soins INCA Territoriaux Cancéropôles Réseaux de soins CNRS HAS Régionaux Coordination Etablissements Ville-Hôpital HAD Groupes IFCT Privés (60%) FNCLCC GOLF Coopérateurs Centrales UCPO d’achat Buying Thésaurus group Sociétés SOR BECT Savantes Psycho- RCP Formation Pharmaciens EFEC Oncologie Cancer info ARC Hospit/Ville SFPO service Oncologue/RT Patient Spé. d’organe Staffs Ligue contre hospitaliers le cancer Infirmières Assoc. Patients AFIC Kiné, Nutrition… Presentation of the French Oncology Market – Lyon - March 2010 9
  10. 10. France boasts an attractive environment in the organization of oncology careand R&D funding /support (1/2)STARTING POINT: NATIONAL CANCER PLAN #1 (2003-2007) 640M€ over a 3-year period to boost cancer diagnostic and screening campaigns, organization of care, access to innovative drugs, research, and training One of the most emblematic measure was the creation of National Cancer Institute (INCA) Launched in 2005 under the authority of both Ministry of Health and Ministry of Research 100+ M€ budget per year to fund research initiatives in oncology (~50% of budget), patient care and information as well as other public health missions Some international collaborations (e.g. US NCI for selected clinical trials)A NEW NATIONAL CANCER PLAN (2009-2013) Launched with 750M€ funding to amplify initiatives of the first plan Presentation of the French Oncology Market – Lyon - March 2010 10
  11. 11. France boasts an attractive environment in the organization of oncology careand R&D funding / support (2/2)EXAMPLES OF NETWORKS ACROSS THE FRENCH TERRITORY Cancéropôles The 7 « Canceropoles » are regional structures with goal to develop the link between patient care and research Four main missions: Set up of tumor banks Development of R&D platforms (genomics, proteomics, …) Funding of clinical trials in oncology Promotion of ad hoc studies in social and human sciences Gathers twenty cancer centres spread across the whole French Territory FNCLCC Created in 1945 as private structures but with public funding Dedicated to oncology treatment, FNCLCC has a role of prevention, research, cares & training within strict quality rules Centers function as public service hospitals which brings together surgeons, medical oncologists and radiotherapists in a cross- disciplinary fashion Presentation of the French Oncology Market – Lyon - March 2010 11
  12. 12. 1. KEY MARKET FIGURES2. RELEVANT NETWORKS & STAKEHOLDERS3. FOCUS ON INDUSTRY PARTICIPANTS Presentation of the French Oncology Market – Lyon - March 2010 12
  13. 13. A dynamic network of biotech start-ups and SMEs both involvedin the development of diagnostics tools and advanced oncology drugs Besides Pharma giant Sanofi and mid-pharmas active in oncology such as Ipsen or Pierre Fabre, France has some innovative SMEs in the oncology field 185 Life sciences SMEs in France Relevant players in oncology Vaccines Transgene, Innate Pharma, 3% Bioalliance Pharma, Cytheris, BiopharmaR&D Tools Erytech Pharma,…& Services 32% 28% Ipsogen, Exonhit, Imaxio in vitro Diagnostic 8% Med Devices 24% in vivo Diagnostic 5% Supersonic Imagine, Mauna Kea TechnologiesSource: Bionest Partners analysis Presentation of the French Oncology Market – Lyon - March 2010 13
  14. 14. 19, rue du Général Foy 75008 Paris France Tel: +33 1 58 05 14 00 Fax: +33 1 58 05 14 0914 Wall Street, 20th floor New York, NY 10005 USA Tel: +1 646 386 2900 Fax: +1 212 832 3227 info@bionest.com www.bionest.com 14

×